Therapeutic Area Market Research Reports & Industry Analysis
Therapeutic areas include Cardiology/Vascular Diseases, Dental and Oral Health, Dermatology, Devices, Endocrinology, Family Medicine, Gastroenterology, Genetic Disease, Healthy Volunteers, Hematology, Hepatology, Immunology, Infections and Infectious Diseases, Internal Medicine, Musculoskeletal, Nephrology, Neurology, Nutrition and Weight Loss, Obstetrics/Gynecology, Oncology, Ophthalmology, Orthopedics/Orthopedic Surgery, Otolaryngology, Pediatrics/Neonatology, Pharmacology/Toxicology, Podiatry, Psychiatry/Psychology, Pulmonary/Respiratory Diseases, Rheumatology, Sleep, Trauma, Urology, and Vaccines.
Reports in these categories will contain statistics of prevalence and growth concerning therapeutic area diseases for which there are product reviews, market size, and share for products that are used in pharmaceutical treatment or equipment that used in surgical treatment of the therapeutic area.
Therapeutic Area Industry Research & Market Reports
-
Nocturia Drugs
... CAGR of 6.1% over the analysis period 2024-2030. Low Nocturnal Bladder Capacity Indication, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.0 Billion by the end ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Pulmonary / Respiratory Drug Delivery
... Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Metered Dose Inhalers, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$35.9 ... Read More
-
Sexual Enhancers
... CAGR of 7.7% over the analysis period 2024-2030. Male Sexual Enhancers, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$354.9 Million by the end of the ... Read More
-
In-Vitro Fertilization
... CAGR of 8.0% over the analysis period 2024-2030. In-Vitro Fertilization Equipment, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$684.2 Million by the end of the ... Read More
-
Malignant Mesothelioma
... CAGR of 6.2% over the analysis period 2024-2030. Premetrexed & Combination Drugs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$518.6 Million by the end of ... Read More
-
Sperm Banks
... CAGR of 5.3% over the analysis period 2024-2030. Sperm Storage Service, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$4.2 Billion by the end of the ... Read More
-
Statins
... 1.8% over the analysis period 2024-2030. Synthetic Statins, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$12.2 Billion by the end of the analysis period. Growth ... Read More
-
Anticoagulants
... 9.2% over the analysis period 2024-2030. NOACs, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$33.4 Billion by the end of the analysis period. Growth in ... Read More
-
Alopecia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Topical Drugs, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$8.4 Billion by the end of the analysis ... Read More
-
Artificial Saliva
... CAGR of 13.5% over the analysis period 2024-2030. Oral Sprays, one of the segments analyzed in the report, is expected to record a 14.3% CAGR and reach US$1.3 Billion by the end of the analysis ... Read More
-
Atopic Dermatitis Drugs
... at a CAGR of 21.1% over the analysis period 2024-2030. Biologics Drug Class, one of the segments analyzed in the report, is expected to record a 22.7% CAGR and reach US$18.7 Billion by the end ... Read More
-
Cancer Diagnostics
... CAGR of 5.8% over the analysis period 2024-2030. Imaging, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$95.3 Billion by the end of the analysis period. ... Read More
-
Artificial Joints
... CAGR of 4.4% over the analysis period 2024-2030. Cemented Joints, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$21.2 Billion by the end of the analysis ... Read More
-
Bovine Respiratory Disease Treatment
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.4 Billion by the end ... Read More
-
Breast Lesion Localization
... at a CAGR of 4.5% over the analysis period 2024-2030. Breast Biopsy, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$309.2 Million by the end of ... Read More
-
Skin Tightening
... CAGR of 6.2% over the analysis period 2024-2030. Radio Frequency Skin Tightening, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$3.3 Billion by the end of ... Read More
-
Skin Allergy Therapeutics
... at a CAGR of 5.3% over the analysis period 2024-2030. The U.S. Market is Estimated at US$492.4 Million While China is Forecast to Grow at 8.3% CAGR The Skin Allergy Therapeutics market in the U.S. ... Read More
-
Pigmentation Disorders Treatment
... at a CAGR of 5.7% over the analysis period 2024-2030. Topical Drugs Treatment, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$4.5 Billion by the end ... Read More
-
Hospital Acquired Infection Treatment
... 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Urinary Tract Infections, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$31.7 Billion by ... Read More
-
Ophthalmic Ultrasound Systems
... at a CAGR of 3.9% over the analysis period 2024-2030. Portable Systems, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$2.4 Billion by the end of ... Read More
-
Rheumatology Therapeutics
... CAGR of 3.2% over the analysis period 2024-2030. Disease Modifying Anti-Rheumatic Drugs (DMARDs), one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$51.3 Billion by the end ... Read More
-
Cancer Vaccines
... CAGR of 9.3% over the analysis period 2024-2030. Preventive Vaccine, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$7.6 Billion by the end of the analysis ... Read More
-
Cancer Immunotherapy Drug Discovery Outsourcing
... Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 13.4% CAGR and reach US$1.5 Billion ... Read More
-
Acne Drugs
... CAGR of 6.9% over the analysis period 2024-2030. Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$9.6 Billion by the end of the analysis ... Read More
Research Assistance
